tbuckley/cabot-search huggingface dataset:
Postural Orthostatic Tachycardia Syndrome: Experience of the Mohamed VI University Hospital
Authors: Noussaiba Malhabi
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

Postural orthostatic tachycardia syndrome (POTS), one of the most prevalent autonomic disorders, presents with a variety of clinical symptoms, including postural tachycardia, dizziness, orthostatic intolerance, syncope, and exercise intolerance. It often develops following viral or bacterial infections. Aims: we aim to study the Epidemiological, Diagnostic, Etiological Profile, and therapeutic approaches in Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and to study the potential association with other dysautonomias in the same patients. Materiel and methods: This is a prospective, descriptive, and analytical cross-sectional study. The patients were collected over one year, counting 53 patients included in our autonomic nervous unit diagnosed with POTS. Results: we found an average age of 25 years, with more female then male, diagnostic wandering took from 3 months to 6 years as a cut-off in our study. Dysautonomias risqué factors found are COVID-19 infection and stressful lifestyle, main symptom is orthostatic intolerance. For our population the therapeutic approach was based on symptomatic treatment initially in particular; abundant drinks, lower limb muscle building, high salt diet, our results are that a check-up will be proposed in 6 months to see the evolution under treatment Conclusions: Management of POTS focuses on educating patients and implementing non-pharmacological strategies to combat orthostatic intolerance, our aim is to improve the quality of life of our patients.
Comparison of Different Intensive Lipid-Lowering Therapies for Patients with Acute Coronary Syndrome: Ezetimibe and Rosuvastatin Versus High-Dose Rosuvastatin
Authors: Noussaiba Malhabi
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

Introduction: Dyslipidaemias is a risk factor for atherosclerosis that leads to unstable atherosclerotic plaque rupture and acute coronary syndrome. Therefore, it is crucial to find a better control of risk factors to prevent the occurrence of a new acute cardiovascular event. Study aims: We aim to determine whether combining ezetimibe with a high-intensity statin would be a more effective and safer alternative therapy compared to high-intensity statin monotherapy for patients with coronary atherosclerotic heart disease. Materiel and methods: 65 patients were randomly assigned to high-intensity rosuvastatin (group 1) (rosuvastatin 20 mg/d, n = 33), or a combination therapy (group 2) (ezetimibe 10 mg/d and rosuvastatin 10 mg/d, n = 32) with a 3 month of follow-up. A lipid and general blood test to assess effectiveness and safety is done in 3 weeks and 3 months. Informed consent from patients is obtained before they participate in the study. Results: The primary endpoint was the proportion of patients who achieved the LDL-C goal of 55mg/dL in the third month: 60% in the second group vs. 33% in the first group, with a statistically significant difference (p=0.001). It was noted that there was a decrease in high-sensitivity C-reactive protein (Crp) without an increase in blood transaminases. Discussion and conclusion: Statin combined with ezetimibe demonstrates significant benefits in lowering LDL-C and preventing cardiovascular as statin high dose in acute coronary syndromes. Our results are consistent with the literature.
How and when do β-Adrenoceptor Ligands Enhance Inotropy in Acute Heart Failure?
Authors: Thomas J. Feuerstein
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

In a recent paper, we highlighted that the super-selective, short-acting β1-adrenoceptor antagonist Landiolol (Feuerstein and Krumpl 2022), which is administered to patients experiencing acute left ventricular decompensation, did not worsen but in fact, improved the cardiovascular status of these patients. The mechanisms previously proposed to explain the beneficial effects of β-blockers, such as Landiolol, in acute heart failure (AHF) are detailed in.
GWAS Identifies <i>CACNA2D3</i> Associated With Asthma and Atopic Dermatitis Multimorbidity in Children
Authors: Dong Yun Kim, Soyeon Lee, Jae Hwa Jung, Yujin Sub, Sumin Lee, Eun Gyul Kim, Mi Na Kim, Soo Yeon Kim, Yoon Hee Kim, Myung Hyun Sohn, Heon Yung Gee, Kyung Won Kim
Journal: Allergy (2025)
Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study
Authors: Siddhartha Sood, Marni Wiseman, Ahmed Bagit, Khalad Maliyar, Muskaan Sachdeva, Abrahim Abduelmula, Michelle James, Fernejoy Leung, Parbeer Grewal, Vimal H Prajapati, Jensen Yeung
Journal: Journal of the American Academy of Dermatology (2025)
Chordal Entanglement following MitraClipTM Implantation Necessitating Open Heart Surgery
Authors: Ajmer Singh
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

MitraClip implantation has become an alternative technique to reduce the severity of mitral regurgitation for patients with prohibitive surgical risk. It can, however, lead to either procedure-related or device-related complications. Here, we describe a patient which the MitraClipTM arms were entangled to the chordae tendinae and papillary muscles, and the device could neither be deployed nor removed. The patient required open heart surgery for the removal of the clips and emergent MV replacement. The remaining perioperative course and follow-up of the patient was unremarkable.
Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer
Authors: Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, Biagio Ricciuti, Joao V Alessi, Allison L Richards, Sam Tischfield, Jessica Williams, Giuseppe Lamberti, Federica Pecci, Alessandro Di Federico, Maisam Makarem, Bruce E Johnson, Mizuki Nishino, Lynette M Sholl, Adam J Schoenfeld, Mark M Awad
Journal: Journal of Thoracic Oncology (2025)
No-Reflow Phenomenon after Primay Percutaneous Coronary Intervention in patients with ST segment elevation myocardial infarction treated with ticagrelor versus clopidogrel plus eptifibatide: A Randomized Clinical Trial
Authors: Mehdi Sheibani
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

Background and Aims No reflow phenomenon (NRP) is one of the essential complications of primary percutaneous intervention (PPCI). Anti-platelets have essential role in prevention of NRP. The aim of this study is comparison the NRP between ticagrelor and clopidogrel+glycoprotein IIb/IIIa Inhibitor in ST elevation myocardial infarction (STEMI) patients candidate for PPCI. Methods From January 2022 to January 2023 in a randomized clinical trial we compare ticagrelor and clopidogrel plus eptifibatide (a glycoprotein IIb/IIIa inhibitor) in terms of NRP and secondary outcome include mortality, stent thrombosis, vascular complications, bleeding complications and major cardiovascular adverse events (MACE). NRP was defined as TIMI flow grade less than 3. Results: 140 patients were randomly assigned to two study groups. Mean age of patients was 59 years and 82% were male. Baseline characteristics and culprit vessels was not significantly different between study groups.NRP at the end of procedure was occurred in 47.5% in ticagrelor group and 53.7% in clopidogrel + eptifibatide group without statistical significant difference (Pvalue: 0.48). Two major and two minor bleeding occurred in in the clopidogrel+eptifibatide group and no bleeding was reported in ticagrelor group. Bleeding complications was not significantly different between study groups. In hospital mortality, vascular complications and MACE were also not significantly different between study groups. Conclusion: Clopidogrel plus eptifibatide in PPCI has similar outcome with ticagrelor and could be administered if ticagrelor is unavailable or prohibited.
Exploring the Association between Anxiety and Atrial Fibrillation using two Quantitative Psychometric Tools: A Systematic Review and Meta-Analysis
Authors: Maxwell Qu
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

Background: Anxiety is widely prevalent, exhibiting higher rates among individuals with chronic health conditions, notably cardiovascular diseases such as atrial fibrillation (AF). Studies have shown interventions targeting anxiety can improve AF outcomes, while AF management can reduce anxiety levels. This study explores the association between AF and anxiety by comparing anxiety levels in AF populations with healthy controls. Materials and Methods: A systematic review adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) principles was conducted to identify relevant studies through medical databases and grey literature sources. Various psychometric tools, including the Spielberger State-Trait Anxiety Inventory (STAI) and Zung's Self-Rating Anxiety Scale (SAS) were considered for assessing anxiety severity. Meta-analysis was performed using a random-effects model to analyse continuous variables, with the overall effect size quantified as the standardized mean difference (SMD). Results: 5 study samples (327 AF patients for STAI-State, 171 AF patients for STAI-Trait) and 3 study samples (209 AF patients) using Zung's SAS were included in the meta-analysis, along with 3 respective control samples. Compared to control groups, AF patients exhibited significantly higher scores for STAI-State (SMD 1.13; CI: 0.57-1.69, p&lt;0.01, I²=81%), STAI-Trait (SMD 0.54; CI: 0.09-0.99, p=0.02, I²=67%), and Zung's SAS (SMD 1.85; CI: 1.58-2.13, p&lt;0.01, I²=22%). Conclusions: AF patients demonstrated elevated levels of anxiety, as indicated by higher STAI and Zung's SAS scores compared to controls. These findings suggest an association between AF and anxiety. The study highlights the importance of addressing mental health disorders in AF patients and vice versa.
“End-stage” Constrictive Pericarditis- Stem cell Therapy
Authors: Ramachandran Muthiah
Journal: Clinical Cardiology and Cardiovascular Interventions (2024)

Aim: To present a case of ‘end-stage’ constrictive pericarditis with clinical manifestations such as ascites mimicking as cirrhosis of liver. Introduction: ‘End-stage’ constrictive pericarditis has been readily confused with cirrhosis of liver in which there may be ascites, but venous pressure is normal and the neck veins are not engorged. There may be cardiac enlargement in other causes of heart failure. Etiology remains unknown in majority of case and inflammatory process play a central role in its development. Case Report: A 67-year old male presented with sudden onset of tachycardia. Clinical examination revealed right-sided heart failure, ‘Egg-shell’ calcification in Chest X-ray and a characteristic echocardiographicfeatures of pericardial constriction such as septal bounce and dynamic respiratory changes in mitral inflow velocity. The patient was advised medical measures since it is in advanced stage. Conclusion: When clinical signs of right heart failure become unresponsive to increased doses of diuretics, constrictive pericarditis is more likely the underlying disease since severe, right-sided failure develops in very advanced, the end-stage of the disease.
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction
Authors: Giovanni Barbara, Imran Aziz, Sarah Ballou, Lin Chang, Alexander C Ford, Shin Fukudo, Samuel Nurko, Carolina Olano, Miguel Saps, Gregory Sayuk, Kewin T H Siah, Lukas Van Oudenhove, Magnus Simrén
Journal: Nature Reviews Gastroenterology & Hepatology (2025)
Early inadequate response to biological agents portends treatment failure at 6 months in patients with psoriasis: a multicenter, prospective cohort study
Authors: Yuxiong Jiang, Lingling Yao, Xiaoyuan Zhong, Dawei Huang, Yu Wang, Yifan Hu, Shuang Xu, Qian Yu, Ying Li, Jiajing Lu, Yuling Shi
Journal: Journal of the American Academy of Dermatology (2025)
Design, Current States, and Challenges of Nanomaterials in Anti-Neuroinflammation: A Perspective on Alzheimer’s Disease
Authors: Xinyang Hong, Tongkai Chen, Yunyun Liu, Jun Li, Dongqing Huang, Kaiyu Ye, Wanchen Liao, Yulin Wang, Mengling Liu, Ping Luan
Journal: Ageing Research Reviews (2025)
Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project
Authors: Yangyupei Yang, Maria Deloria Knoll, Carly Herbert, Julia C Bennett, Daniel R Feikin, Maria Garcia Quesada, Marissa K Hetrich, Scott L Zeger, Eunice W Kagucia, Melody Xiao, Adam L Cohen, Mark van der Linden, Mignon du Plessis, Inci Yildirim, Brita A Winje, Emmanuelle Varon, Maria Teresa Valenzuela, Palle Valentiner-Branth, Anneke Steens, J Anthony Scott, Larisa Savrasova, Juan Carlos Sanz, Aalisha Sahu Khan, Kazunori Oishi, Néhémie Nzoyikorera, J Pekka Nuorti, Jolita Mereckiene, Kimberley McMahon, Allison McGeer, Grant A Mackenzie, Laura MacDonald, Shamez N Ladhani, Karl G Kristinsson, Jackie Kleynhans, James D Kellner, Sanjay Jayasinghe, Pak-Leung Ho, Markus Hilty, Laura L Hammitt, Marcela Guevara, Charlotte Gilkison, Ryan Gierke, Stefanie Desmet, Philippe De Wals, Ron Dagan, Edoardo Colzani, Pilar Ciruela, Urtnasan Chuluunbat, Guanhao Chan, Romina Camilli, Michael G Bruce, Maria-Cristina C Brandileone, Krow Ampofo, Katherine L O'Brien, Kyla Hayford
Journal: Journal of Infection (2025)
Comparative Analyses of Hidradenitis Suppurativa Surgical Methods: A Systematic Review and Meta-Analysis
Authors: Kaiyang Li, Katya Peri, Vincent Piguet, Lily Xu, Areeba Chaudhry, Rafael Paolo Lansang, Naila Bouadi, Jessica Asgarpour, Stephanie Goldberg, David O Croitoru
Journal: Journal of the American Academy of Dermatology (2025)
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literature
Authors: Oluwaseyi Adeuyan, Celine M Schreidah, Jeffrey W Craig, Werner Kempf, Erika Morsia, Jose A Plaza, Christina Mitteldorf, Alessandro Pileri, Larisa J Geskin, Alejandro A Gru
Journal: Journal of the American Academy of Dermatology (2025)
Intestinal <i>Bacteroides</i> drives glioma progression by regulating CD8+ T cell tumor infiltration
Authors: Jit Chatterjee, Xuanhe Qi, Rui Mu, Xuanwei Li, Talia Eligator, Megan Ouyang, Stephanie L Bozeman, Rachel Rodgers, Somya Aggarwal, Danielle E Campbell, Lawrence A Schriefer, Megan T Baldridge, David H Gutmann
Journal: Neuro-Oncology (2025)

Abstract Background The intestinal microbiota regulates normal brain physiology and the pathogenesis of several neurological disorders. While prior studies suggested that this regulation operates through immune cells, the underlying mechanisms remain unclear. Leveraging two well characterized murine models of low-grade glioma (LGG) occurring in the setting of the neurofibromatosis type 1 (NF1) cancer predisposition syndrome, we sought to determine the impact of the gut microbiome on optic glioma progression. Methods Nf1-mutant mice genetically engineered to develop optic pathway gliomas (Nf1OPG mice) by 3 months of age were reared under germ-free (GF) conditions, treated with specific cocktails of antibiotics, or given fecal matter transplants (FMTs). Intestinal microbial species were identified by 16S genotyping. Neutralizing TGFβ antibodies were delivered systemically, while in vitro experiments used isolated murine microglia and T cells. Single cell RNA sequencing analysis was performed using established methods. Results Nf1 OPG mice raised in a GF environment or postnatally treated with vancomycin did not harbor optic gliomas or exhibit OPG-induced retinal nerve fiber layer thinning, which was reversed following conventionally raised mouse FMT or colonization with Bacteroides species. Moreover, this intestinal microbiota-regulated gliomagenesis was mediated by circulating TGFβ, such that systemic TGFβ neutralization reduced Nf1-OPG growth. TGFβ was shown to act on tumor-associated monocytes to induce Ccl3 expression and recruit CD8+ T cells necessary for glioma growth. Conclusions Taken together, these findings establish, for the first time, a mechanistic relationship between Bacteroides in the intestinal microbiome and NF1-LGG pathobiology, suggesting both future predictive risk assessment strategies and therapeutic opportunities.
Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second‐line therapy for patients with metastatic colorectal cancer.
Authors: Yongkun Sun, Jing Zhang, Wenwei Yang, Guifu Wu, Xiaomin Zhong, Wen Zhang, Ping Liang, Baoqi Li, Chengxu Cui
Journal: Journal of Clinical Oncology (2025)

155 Background: Metastatic colorectal cancer (mCRC) patients have poor prognoses with limited response to second-line chemotherapy. Therefore, it is urgent to refine and design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients with mCRC. This study assessed the safety and efficacy of the trifluridine/tipiracil (TAS-102), irinotecan, and bevacizumab regimen in second-line settings for mCRC patients. Methods: This was a multicenter, single-arm, phase II trial. The mCRC patients who are refractory to standard first-line treatment, including fluoropyrimidine and oxaliplatin, are eligible. Based on the recommended phase II dose established in phase I, enrolled patients received TAS-102 (30 mg/m2 twice daily on days 1-5) and irinotecan (150 mg/m2 on day 1) combined with bevacizumab (5 mg/kg on day 1) every two weeks. The primary endpoint was the objective response rate (ORR). Results: Between October 1, 2023, and August 31, 2024, 60 patients were enrolled, and all of them were evaluated for efficacy. As of August 31, 2024, efficacy was assessed in all 60 participants with an ORR of 18.3% (2 had complete response, CR; 9 had partial response, PR; 39 had stable disease, SD). Among the 39 patients with SD, 29 patients experienced tumor shrinkage. The disease control rate (DCR) was 83.3%. The median follow-up was 8.6 months (95% confidence interval [CI], 6.743-10.457). The six-month progression-free survival (PFS) was 59.6%. The median PFS was 6.9 months (95% CI 5.016-8.784), whereas the median overall survival (OS) was not reached. The 1-year OS rate was 92%. At the time of analysis, four patients have died, and 56 patients are still alive. All patients were evaluable for safety assessment. The most common treatment-related adverse events (TRAE) were nausea (100%), neutropenia (86.7%), and anemia (83.3%). The most frequent grade 3/4 TRAE were neutropenia (48.3%), febrile neutropenia (8.3%), nausea (3.3%), and anemia (3.3%). No treatment-related death occurred. Conclusions: The regimen of irinotecan, TAS-102, plus bevacizumab preliminarily demonstrated promising efficacy with tolerable toxicity for mCRC patients as second‐line treatment. This regimen warrants further exploration in refractory mCRC patients. Clinical trial information: NCT06202001 .
Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with <i>RAS</i> wild-type metastatic colorectal cancer: Nationwide real-world data.
Authors: Chao-Yuan Wang
Journal: Journal of Clinical Oncology (2025)

57 Background: This study investigated the efficacy and safety of anti-epidermal growth factor receptor (EGFR) agents plus chemotherapy for elderly patients (aged &gt; or = 70 years) with RAS wild-type metastatic colorectal cancer (mCRC) from nationwide data in Taiwan. Methods: Total 756 patients with RAS wild-type mCRC who received first-line therapy with anti-EGFR agents (Cetuximab) plus chemotherapy at nationwide multiple institutions from November 2016 to January 2021. The study explored the prognostic impact between two age groups (≥70 vs &lt;70). Progression-free survival (PFS) and cancer-specific survival (CSS) were compared. Additionally, severe adverse events (SAEs) were also compared between two age groups. Results: The median PFS and CSS were comparable between the two age groups (14.0 vs 14.0 months, p = 0.098; 32.0 vs 35.0 months, p = 0.226, respectively). Moreover, subgroup analysis revealed similar PFS and CSS between two age groups in patients with synchronous or metachronous mCRC and left-sided or right-sided tumors (all p &gt; 0.05). Regarding hematologic SAEs, a significant higher incidence of grade ≥ 3 anemia was found in elderly patient group (13.3% vs 5.0%, p = 0.003). However, no significant difference was observed in the incidence of non-hematologic SAEs (all p &gt; 0.05). Conclusions: According to this nationwide real-world data, for patients carrying RAS wild-type mCRC treated with cetuximab plus chemotherapy, elderly patients could have comparable benefit as younger ones. Except for grade ≥ 3 anemia, other hematologic SAEs and non-hematologic SAEs revealed no significant difference between two age groups.
Effects of tumor treating fields (TTFields) with FOLFIRINOX on BRCA WT pancreatic cancer cells.
Authors: Michael Zheng, Hila Ene, Kerem Ben Meir, Hila Gabay, Eyal Dor-On, Adi Haber, Moshe Giladi, Yoram Palti
Journal: Journal of Clinical Oncology (2025)

753 Background: Pancreatic cancer remains one of the most aggressive malignancies, frequently diagnosed at the locally advanced or metastatic stage. In the advanced setting, first-line chemotherapy options include gemcitabine with nab-paclitaxel or FOLFIRINOX, a combination regimen of fluorouracil, oxaliplatin, irinotecan and leucovorin. The FOLFIRINOX regimen is however associated with greater toxicity and is hence used only in patients with good performance status. BRCA-mutated tumors seem to be more sensitive to FOLFIRINOX due to the DNA-damaging, platinum-based component of this treatment regimen. Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes crucial for cancer cell viability that have shown efficacy in preclinical pancreatic cancer models; and, in various cancer types, have been shown to reduce expression of proteins from the BRCA-dependent DNA repair pathway. The current study examined the potential use of TTFields for sensitization of BRCA wild-type pancreatic cancer cells to treatment with FOLFIRINOX. Methods: Human pancreatic BRCA wild-type cancer cells BxPC3 and AsPC1 were treated with TTFields (150 kHz; 0.7 and 1 V/cm RMS, respectively), using the inovitro device. FOLFIRINOX was administered to the cells at increasing concentrations, with or without co-treatment with TTFields. After 72h of treatment, cell count, colony formation, and apoptosis were measured. For mechanistical insight, gene and protein expression were evaluated following 24, 48, or 72h of TTFields treatment. Results: TTFields application to the pancreatic cells together with FOLFIRINOX elevated the cytotoxic, clonogenic and apoptotic effects induced by FOLFIRINOX or TTFields alone. RNA sequencing data revealed that TTFields downregulated DNA damage repair, DNA replication, and cell cycle related processes. Specifically, real-time PCR and Western blot analysis demonstrated reduced expression of several central players in the BRCA DNA damage repair pathway. Conclusions: TTFields application together with FOLFIRINOX in pancreatic cancer cells lacking background BRCA mutations exhibits potential improvement relative to FOLFIRINOX alone, that may be rationalized based on downregulation of key DNA repair pathways. Future studies should explore the possibility of reducing FOLFIRINOX treatment dose, potentially alleviating FOLFIRINOX-related toxicity.